https://idataresearch.com/wp-content/themes/lambda-child-theme/images/footer-logo.png
https://idataresearch.com/wp-content/themes/lambda-child-theme/images/idata-white-logo.png

Immunology

Showing 17–29 of 29 results

Immunology Drugs Market Overview | United States | 2018-2024 | MedView

The U.S. immunology market includes biologic drugs that are used in the treatment of various immunology diseases such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn`s disease (CD), ulcerative colitis (UC) and psoriasis (PsO). As there is a need for cost effective drugs in treating these diseases, there is an increased number of drugs in development for these diseases. Current treatment mainly constitutes NSAIDs and biologics. However, this report is limited to biologics, as they constitute 90% of the revenue in immunology. The reports covers second line treatments, their dosage, comparative cost studies, market size and revenue forecasts.

more...

Ulcerative Colitis Drug Market Analysis | United States | 2018-2024 | MedCore

This market report includes a detailed analysis of the drugs used to treat ulcerative colitis in the US, including Entyvio, Humira, Remicade, and Simponi. The ulcerative colitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

more...

Immunology Drugs Product Portfolio and Pipeline | United States | 2018-2024 | MedFolio

The Immunology Drug Product Portfolio contains Drug Classifications, Product Assessment, Data by Company, Price Analysis by Retail and Veteran Discounts for biologics such as ORENCIA®, HUMIRA®, CIMZIA®, Enbrel®, SIMPONI®, REMICADE®, RITUXAN®, Actemra®, STELARA®, ENTYVIO® and TYSABRI®.

more...

Psoriasis Drug Market Analysis | United States | 2018-2024 | MedCore

This market report includes a detailed analysis of the drugs used to treat psoriasis in the US, including Humira, Enbrel, Remicade, and Stelera. The psoriasis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

more...

Rheumatoid Arthritis Drug Market Analysis | United States | 2018-2024 | MedCore

This market report includes a detailed analysis of the drugs used to treat rheumatoid arthritis in the US, including Orencia, Humira, Cimzia, Enbrel, Simponi, Remicade, Rituxan, Actemra, and Xeljanz. The rheumatoid arthritis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

more...

Ankylosing Spondylitis Drug Market Analysis | United States | 2018-2024 | MedCore

This market report includes a detailed analysis of the drugs used to treat ankylosing spondylitis in the US, including Humira, Cimzia, Enbrel, Simponi, and Remicade. The ankylosing spondylitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

more...

Crohn’s Disease Drug Market Analysis | United States | 2018-2024 | MedCore

This market report includes a detailed analysis of the drugs used to treat Crohn’s disease in the US, including Humira, Cimzia, Remicade, Stelara, Entyvio, and Tysabri. The Crohn’s disease drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

more...

Crohn’s Disease Drug Market Analysis | Europe | 2018-2024 | MedCore

This market report includes a detailed analysis of the drugs used to treat Crohn’s disease in Europe, including Humira, Cimzia, Remicade, Stelara, Entyvio, and Tysabri. The Crohn’s disease drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

more...

Ankylosing Spondylitis Drug Market Analysis | Europe | 2018-2024 | MedCore

This market report includes a detailed analysis of the drugs used to treat ankylosing spondylitis in Europe, including Humira, Cimzia, Enbrel, Simponi, and Remicade. The ankylosing spondylitis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

more...

Rheumatoid Arthritis Drug Market Analysis | Europe | 2018-2024 | MedCore

This market report includes a detailed analysis of the drugs used to treat rheumatoid arthritis in Europe, including Orencia, Humira, Cimzia, Enbrel, Simponi, Remicade, Rituxan, Actemra, and Xeljanz. The rheumatoid arthritis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

more...

Psoriasis Drug Market Analysis | Europe | 2018-2024 | MedCore

This market report includes a detailed analysis of the drugs used to treat psoriasis in Europe, including Humira, Enbrel, Remicade, and Stelera. The psoriasis drug market is largely driven by the expiry of patents and the entry of biosimilars which present strong competition for the biologics listed above.

more...

Immunology Drug Product Portfolio and Pipeline | Europe | 2018-2024 | MedFolio

The Immunology Drug Product Portfolio contains Drug Classifications, Product Assessment, Data by Company, Price Analysis by Retail and Veteran Discounts for biologics such as ORENCIA®, HUMIRA®, CIMZIA®, Enbrel®, SIMPONI®, REMICADE®, RITUXAN®, Actemra®, STELARA®, ENTYVIO® and TYSABRI®.

more...

Psoriasis Cream and Medication Market Report Suite | United States | 2009-2015 | MedSuite

The psoriasis treatment market includes all over-the-counter and prescription pharmaceutical products used to treat psoriasis. This includes topical tar, salicylic acid, corticosteroids, combination corticosteroids, vitamin D analogs, anthralin, retinoids, methotrexate, cyclosporine, and biologic treatments.

more...